Volume 14 Issue 1
Jan.  2023
Turn off MathJax
Article Contents
Liu Qixing, Li Yuehong. The latest progress on novel coronavirus vaccination in kidney transplant recipients[J]. ORGAN TRANSPLANTATION, 2023, 14(1): 135-141. doi: 10.3969/j.issn.1674-7445.2023.01.018
Citation: Liu Qixing, Li Yuehong. The latest progress on novel coronavirus vaccination in kidney transplant recipients[J]. ORGAN TRANSPLANTATION, 2023, 14(1): 135-141. doi: 10.3969/j.issn.1674-7445.2023.01.018

The latest progress on novel coronavirus vaccination in kidney transplant recipients

doi: 10.3969/j.issn.1674-7445.2023.01.018
More Information
  • Corresponding author: Li Yuehong, Email: lyha01051@btch.edu.cn
  • Received Date: 2022-08-19
    Available Online: 2023-01-17
  • Publish Date: 2023-01-15
  • Due to long-term use of immunosuppressant, poor immune function and a higher risk of critical diseases after novel coronavirus pneumonia in kidney transplant recipients, it is of significance to deliver prophylactic vaccination for this high-risk population. Studies have shown that the immune reaction of kidney transplant recipients to novel coronavirus vaccine is significantly lower than that of healthy counterparts. Standard vaccination program in the United States, such as 2 doses of messenger RNA (mRNA) vaccine, fails to provide sufficient protection for kidney transplant recipients. Many studies have proven that increasing the frequency of vaccination for kidney transplant recipients may enhance the vaccine efficacy. Nevertheless, the role of adjusting immunosuppressive therapy in increasing vaccine efficacy remains to be elucidated. In this article, the importance, effectiveness and particularity of novel coronavirus vaccine for kidney transplant recipients and the effect of immunosuppressive therapy on the efficacy of novel coronavirus vaccine were reviewed, aiming to provide reference on the vaccination for kidney transplant recipients.

     

  • loading
  • [1]
    CAILLARD S, ANGLICHEAU D, MATIGNON M, et al. An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants[J]. Kidney Int, 2020, 98(6): 1549-1558. DOI: 10.1016/j.kint.2020.08.005.
    [2]
    CRAVEDI P, MOTHI SS, AZZI Y, et al. COVID-19 and kidney transplantation: results from the TANGO International Transplant Consortium[J]. Am J Transplant, 2020, 20(11): 3140-3148. DOI: 10.1111/ajt.16185.
    [3]
    GANDOLFINI I, CRESPO M, HELLEMANS R, et al. Issues regarding COVID-19 in kidney transplantation in the ERA of the Omicron variant: a commentary by the ERA Descartes Working Group[J]. Nephrol Dial Transplant, 2022, 37(10): 1824-1829. DOI: 10.1093/ndt/gfac203.
    [4]
    COCHRAN W, SHAH P, BARKER L, et al. COVID-19 clinical outcomes in solid organ transplant recipients during the Omicron surge[J]. Transplantation, 2022, 106(7): e346-e347. DOI: 10.1097/TP.0000000000004162.
    [5]
    BERTRAND D, LAURENT C, LEMÉE V, et al. Efficacy of anti-SARS-CoV-2 monoclonal antibody prophylaxis and vaccination on the Omicron variant of COVID-19 in kidney transplant recipients[J]. Kidney Int, 2022, 102(2): 440-442. DOI: 10.1016/j.kint.2022.05.007.
    [6]
    SAHIN U, MUIK A, VOGLER I, et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans[J]. Nature, 2021, 595(7868): 572-577. DOI: 10.1038/s41586-021-03653-6.
    [7]
    KHOURY DS, CROMER D, REYNALDI A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection[J]. Nat Med, 2021, 27(7): 1205-1211. DOI: 10.1038/s41591-021-01377-8.
    [8]
    FIOLET T, KHERABI Y, MACDONALD CJ, et al. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review[J]. Clin Microbiol Infect, 2022, 28(2): 202-221. DOI: 10.1016/j.cmi.2021.10.005.
    [9]
    CAILLARD S, THAUNAT O. COVID-19 vaccination in kidney transplant recipients[J]. Nat Rev Nephrol, 2021, 17(12): 785-787. DOI: 10.1038/s41581-021-00491-7.
    [10]
    SATTLER A, SCHREZENMEIER E, WEBER UA, et al. Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (Tozinameran) prime-boost vaccination in kidney transplant recipients[J]. J Clin Invest, 2021, 131(14): e150175. DOI: 10.1172/JCI150175.
    [11]
    CAILLARD S, CHAVAROT N, BERTRAND D, et al. Occurrence of severe COVID-19 in vaccinated transplant patients[J]. Kidney Int, 2021, 100(2): 477-479. DOI: 10.1016/j.kint.2021.05.011.
    [12]
    BENNING L, MORATH C, BARTENSCHLAGER M, et al. Neutralization of SARS-CoV-2 variants of concern in kidney transplant recipients after standard COVID-19 vaccination[J]. Clin J Am Soc Nephrol, 2022, 17(1): 98-106. DOI: 10.2215/CJN.11820921.
    [13]
    AL JURDI A, GASSEN RB, BORGES TJ, et al. Suboptimal antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipients[J]. Kidney Int, 2022, 101(6): 1282-1286. DOI: 10.1016/j.kint.2022.04.009.
    [14]
    KAMAR N, ABRAVANEL F, MARION O, et al. Three doses of an mRNA COVID-19 vaccine in solid-organ transplant recipients[J]. N Engl J Med, 2021, 385(7): 661-662. DOI: 10.1056/NEJMc2108861.
    [15]
    BENOTMANE I, GAUTIER G, PERRIN P, et al. Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses[J]. JAMA, 2021, 326(11): 1063-1065. DOI: 10.1001/jama.2021.12339.
    [16]
    HALL VG, FERREIRA VH, KU T, et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients[J]. N Engl J Med, 2021, 385(13): 1244-1246. DOI: 10.1056/NEJMc2111462.
    [17]
    MASSET C, KERLEAU C, GARANDEAU C, et al. A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response[J]. Kidney Int, 2021, 100(5): 1132-1135. DOI: 10.1016/j.kint.2021.08.017.
    [18]
    MASSA F, CREMONI M, GÉRARD A, et al Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients[J]. EBioMedicine, 2021, 73: 103679. DOI: 10.1016/j.ebiom.2021.103679.
    [19]
    KUMAR D, HU Q, SAMSON R, et al. Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine[J]. Am J Transplant, 2022, 22(8): 2089-2093. DOI: 10.1111/ajt.17020.
    [20]
    CAILLARD S, THAUNAT O, BENOTMANE I, et al. Antibody response to a fourth messenger RNA COVID-19 vaccine dose in kidney transplant recipients: a case series[J]. Ann Intern Med, 2022, 175(3): 455-456. DOI: 10.7326/L21-0598.
    [21]
    OSMANODJA B, RONICKE S, BUDDE K, et al. Serological response to three, four and five doses of SARS-CoV-2 vaccine in kidney transplant recipients[J]. J Clin Med, 2022, 11(9): 2565. DOI: 10.3390/jcm11092565.
    [22]
    BENOTMANE I, BRUEL T, PLANAS D, et al. A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients[J]. Kidney Int, 2022, 101(5): 1073-1076. DOI: 10.1016/j.kint.2022.02.011.
    [23]
    CHARMETANT X, ESPI M, BENOTMANE I, et al. Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients[J]. Sci Transl Med, 2022, 14(636): eabl6141. DOI: 10.1126/scitranslmed.abl6141.
    [24]
    BENOTMANE I, GAUTIER-VARGAS G, GALLAIS F, et al. Strong antibody response after a first dose of a SARS-CoV-2 mRNA-based vaccine in kidney transplant recipients with a previous history of COVID-19[J]. Am J Transplant, 2021, 21(11): 3808-3810. DOI: 10.1111/ajt.16764.
    [25]
    BENNING L, MORATH C, BARTENSCHLAGER M, et al. Natural SARS-CoV-2 infection results in higher neutralization response against variants of concern compared with 2-dose BNT162b2 vaccination in kidney transplant recipients[J]. Kidney Int, 2022, 101(3): 639-642. DOI: 10.1016/j.kint.2021.12.009.
    [26]
    ZONG K, PENG D, YANG H, et al. Risk factors for weak antibody response of SARS-CoV-2 Vaccine in adult solid organ transplant recipients: a systemic review and meta-analysis[J]. Front Immunol, 2022, 13: 888385. DOI: 10.3389/fimmu.2022.888385.
    [27]
    ROZEN-ZVI B, YAHAV D, AGUR T, et al. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study[J]. Clin Microbiol Infect, 2021, 27(8): 1173. e1-1173. e4. DOI: 10.1016/j.cmi.2021.04.028.
    [28]
    KANTAUSKAITE M, MÜLLER L, KOLB T, et al. Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients[J]. Am J Transplant, 2022, 22(2): 634-639. DOI: 10.1111/ajt.16851.
    [29]
    NETTI GS, INFANTE B, TROISE D, et al. mTOR inhibitors improve both humoral and cellular response to SARS-CoV-2 messenger RNA BNT16b2 vaccine in kidney transplant recipients[J]. Am J Transplant, 2022, 22(5): 1475-1482. DOI: 10.1111/ajt.16958.
    [30]
    CHAVAROT N, OUEDRANI A, MARION O, et al. Poor anti-SARS-CoV-2 humoral and T-cell responses after 2 injections of mRNA vaccine in kidney transplant recipients treated with belatacept[J]. Transplantation, 2021, 105(9): e94-e95. DOI: 10.1097/TP.0000000000003784.
    [31]
    REGELE F, HEINZEL A, HU K, et al. Stopping of mycophenolic acid in kidney transplant recipients for 2 weeks peri-vaccination does not increase response to SARS-CoV-2 vaccination-a non-randomized, controlled pilot study[J]. Front Med (Lausanne), 2022, 9: 914424. DOI: 10.3389/fmed.2022.914424.
    [32]
    BENOTMANE I, GAUTIER-VARGAS G, COGNARD N, et al. Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine[J]. Kidney Int, 2021, 99(6): 1498-1500. DOI: 10.1016/j.kint.2021.04.005.
    [33]
    GRUPPER A, RABINOWICH L, SCHWARTZ D, et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus[J]. Am J Transplant, 2021, 21(8): 2719-2726. DOI: 10.1111/ajt.16615.
    [34]
    MARION O, DEL BELLO A, ABRAVANEL F, et al. Safety and immunogenicity of anti-SARS-CoV-2 messenger RNA vaccines in recipients of solid organ transplants[J]. Ann Intern Med, 2021, 174(9): 1336-1338. DOI: 10.7326/M21-1341.
    [35]
    CUCCHIARI D, EGRI N, BODRO M, et al. Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients[J]. Am J Transplant, 2021, 21(8): 2727-2739. DOI: 10.1111/ajt.16701.
    [36]
    MIDTVEDT K, TRAN T, PARKER K, et al. Low immunization rate in kidney transplant recipients also after dose 2 of the BNT162b2 vaccine: continue to keep your guard up![J]. Transplantation, 2021, 105(8): e80-e81. DOI: 10.1097/TP.0000000000003856.
    [37]
    WERBEL WA, BOYARSKY BJ, OU MT, et al. Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series[J]. Ann Intern Med, 2021, 174(9): 1330-1332. DOI: 10.7326/L21-0282.
    [38]
    STUMPF J, TONNUS W, PALIEGE A, et al. Cellular and humoral immune responses after 3 doses of BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant[J]. Transplantation, 2021, 105(11): e267-e269. DOI: 10.1097/TP.0000000000003903.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(1)

    Article Metrics

    Article views (307) PDF downloads(92) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return